Investment Analysts’ Weekly Ratings Updates for Relx (RELX)
by Kim Johansen · The Markets DailyRelx (NYSE: RELX) has recently received a number of price target changes and ratings updates:
- 10/20/2026 – Relx was downgraded by Citigroup Inc. from “buy” to “neutral”.
- 10/6/2026 – Relx had its “buy” rating reaffirmed by Sanford C. Bernstein.
- 9/30/2026 – Relx was upgraded by Zacks Research from “hold” to “strong-buy”.
- 9/29/2026 – Relx had its “buy” rating reaffirmed by UBS Group AG.
- 9/13/2026 – Relx was downgraded by Wall Street Zen from “buy” to “hold”.
- 9/11/2026 – Relx was upgraded by TD Securities to “strong-buy”.
- 9/10/2026 – Relx is now covered by TD Cowen. They set a “buy” rating on the stock.
- 9/5/2026 – Relx was upgraded by Wall Street Zen from “hold” to “buy”.
Relx Cuts Dividend
The company also recently disclosed a dividend, which was paid on Tuesday, September 15th. Investors of record on Friday, August 7th were issued a dividend of $0.2785 per share. The ex-dividend date of this dividend was Friday, August 7th. This represents a dividend yield of 157.0%. This is a decrease from Relx’s previous dividend of $0.6559.
RELX PLC is a global information-based analytics and decision tools company serving professional and business customers. The company provides data, software, research, and workflow solutions that help organizations make decisions, manage risk, improve productivity, and access specialized knowledge.
Its main business areas include scientific, technical, and medical information; risk and business analytics; legal information and technology; and industry-focused events. Products and services include research platforms such as ScienceDirect and Scopus, legal research and workflow solutions offered through LexisNexis, and risk-management, fraud-prevention, and identity solutions provided through LexisNexis Risk Solutions.
RELX serves customers internationally, including universities, researchers, law firms, government agencies, insurers, financial institutions, corporations, and healthcare professionals.
Read More
- Five stocks we like better than Relx
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge